<DOC>
	<DOCNO>NCT01051765</DOCNO>
	<brief_summary>Irinotecan , one new agent use advanced esophageal carcinoma , show effective safe western study . Different western , squamous carcinoma main pathological type china patient . The investigator initiate prospective phase II clinical trial irinotecan/cisplatin 1st line treatment advance esophageal carcinoma observe efficacy safety combination .</brief_summary>
	<brief_title>Irinotecan Combined With Cisplatin 1st Line Treatment Esophageal Squamous Cell Cancer : Single Center Prospective Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Having sign informed consent Age 18 70 year old Histologically confirm esophageal squamous carcinoma , prior palliative chemotherapy ; recurrence last adjuvant chemotherapy adjuvant radiotherapy longer 6 month ; prior treatment irinotecan adjuvant chemotherapy , total dose cisplatin le 300mg/m2 used adjuvant chemotherapy Unresectable recurrent metastatic disease Measurable disease accord RECIST criterion ( diameter lesion 10mm spiral CT MRI , 20mm common CT , date image le 15 day enrollment ) Karnofsky performance status ≥70 Life expectancy ≥3 month No prior radiotherapy except radiotherapy nontarget lesion study 4 week ALT AST &lt; 2.5 time ULN ( ≤5 time ULN patient liver metastasis ) ( within 7 day enrollment ) Serum AKP &lt; 2.5 time ULN ( within 7 day enrollment ) Serum creatinine &lt; 1.0 time ULN ( within 7 day enrollment ) Bilirubin level &lt; 1.0 time ULN ( within 7 day enrollment ) WBC &gt; 4,000/mm3 , absolute neutrophil count ≥2000/mm3 , platelet &gt; 100,000/mm3 , Hb &gt; 9g/dl ( within 7 day enrollment ) No sever complication , active gastrointestinal bleeding , perforation , jaundice , obstruction , noncancerous fever＞38℃； Good compliance previous treatment palliative chemotherapy recurrence le 6 month time last adjuvant chemo/radiotherapy Known hypersensitivity irinotecan Only Brain bone metastasis Tumor length≥10cm , liver metastasis cover 50 % liver , lung metastasis cover 25 % lung No measurable lesion , eg . pleural fluid ascites Surgery ( exclude diagnostic biopsy ) within 4 week prior study entry Heart failure sever organ dysfunction , eg . coronary artery disease , myocardial infarction within last 6 month Pregnancy lactation period Other previous malignancy within 5 year , except nonmelanoma skin cancer Chronic diarrhea Mentally abnormal disable cognition , include CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>